NCT05448768

Brief Summary

This study aims to examine the effects and potential mechanisms of theta-burst stimulation (TBS) on cognitive function in individuals with mild cognitive impairment (MCI).

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
13mo left

Started Sep 2022

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress77%
Sep 2022Jun 2027

First Submitted

Initial submission to the registry

June 27, 2022

Completed
10 days until next milestone

First Posted

Study publicly available on registry

July 7, 2022

Completed
2 months until next milestone

Study Start

First participant enrolled

September 13, 2022

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2027

Last Updated

March 23, 2026

Status Verified

March 1, 2026

Enrollment Period

4.8 years

First QC Date

June 27, 2022

Last Update Submit

March 19, 2026

Conditions

Keywords

Mild Cognitive Impairmenttheta-burst stimulationrepetitive transcranial magnetic stimulation (rTMS)

Outcome Measures

Primary Outcomes (2)

  • Mini-Mental State Examination ( MMSE )

    Change from baseline Mini-Mental State Examination total scores immediately after TBS intervention

    Baseline and immediately after 2 weeks of TBS and 8-week follow-up after TBS

  • Montreal Cognitive Assessment

    Change from baseline Montreal Cognitive Assessment total scores immediately after TBS intervention

    Baseline and immediately after 2 weeks of TBS and 8-week follow-up after TBS

Secondary Outcomes (1)

  • The standard uptake values changes of FDG-PET

    Before and immediately after TBS intervention

Study Arms (2)

Amyloid-positive MCI

ACTIVE COMPARATOR

The subjects will receive active stimulation of standard intermittent TBS (iTBS) protocol.

Device: TBS for Amyloid-positive MCI

Amyloid-negative MCI

ACTIVE COMPARATOR

The subjects will receive active stimulation of standard intermittent TBS (iTBS) protocol.

Device: TBS for Amyloid-negative MCI

Interventions

The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.

Amyloid-positive MCI

The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.

Amyloid-negative MCI

Eligibility Criteria

Age50 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects aged 50-90 year
  • Subjects meet Petersen's criteria for mild cognitive impairment (Petersen, Smith et al. 1999)
  • The CDR of MCI patients can be 0-0.5
  • Amyloid PET should ever be performed

You may not qualify if:

  • Any subject has a definite diagnosis of epilepsy or history of seizure attack.
  • Current or past history of clinically significant neurological insults affecting brain structure or function like completed stroke, head injury or brain tumor.
  • Any subject has clinically significant or unstable medical diseases including metabolic, renal,liver, lung or cardiovascular disorders including metabolic, renal, liver, lung or cardiovascular disorders.
  • Any subject has current alcohol or other substances abuse and/ or dependence within the recent one year, or prolonged history of major psychiatric disorder like schizophrenia,bipolar disorder, and previously prolonged substances abuse.
  • Any females who is pregnant or lactating.
  • Withdrawal criteria
  • Complications onset after intervention that affect efficacy and safety judgments.
  • New onset or progression of disease that may affect outcomes.
  • Use of other therapies or drugs during the intervention period to change cognitive functions.
  • Any subjects who are recognized as high risk of adverse effects by principle investigator.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chang Gung Memorial Hospital

Taoyuan District, Taiwan

Location

MeSH Terms

Conditions

Cognitive Dysfunction

Condition Hierarchy (Ancestors)

Cognition DisordersNeurocognitive DisordersMental Disorders

Study Officials

  • KUAN YI WU

    Chang Gung Memorial Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, we will give two sessions of iTBS separated by 15 min.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 27, 2022

First Posted

July 7, 2022

Study Start

September 13, 2022

Primary Completion (Estimated)

June 30, 2027

Study Completion (Estimated)

June 30, 2027

Last Updated

March 23, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations